<DOC>
	<DOCNO>NCT02381366</DOCNO>
	<brief_summary>PNEUMOSTEM® consist ex vivo culture allogeneic , unrelated , human umbilical cord blood-derived mesenchymal stem cell ( hUCB-MSCs ) intend use cellular therapy product prevention Bronchopulmonary Dysplasia ( BPD ) . This study open-label , single-center , dose escalation study evaluate safety efficacy PNEUMOSTEM® premature infant high risk BPD .</brief_summary>
	<brief_title>Safety Efficacy PNEUMOSTEM® Premature Infants High Risk Bronchopulmonary Dysplasia ( BPD ) - US Study</brief_title>
	<detailed_description />
	<mesh_term>Premature Birth</mesh_term>
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Bronchopulmonary Dysplasia</mesh_term>
	<criteria>A male female infant whose postnatal age 3 14 day , inclusive ( treatment 5 14 day birth ) A subject whose gestational age 23 28 week ( 23 week ≤ gestational age ( GA ) &lt; 28 week ) A subject whose birth weight 500g 1000g , inclusive A subject intubate receive mechanical ventilation within 514 day birth , fraction inspire oxygen ( FiO2 ) 0.25 great Screening A subject either deterioration change set mechanical ventilation within 24 hour trial enrollment A subject whose parent/guardian give write informed consent A subject congenital heart defect , except patent ductus arteriosus ( PDA ) , atrial septal defect ( ASD ) small , restrictive ventricular septal defect ( VSD ) A subject serious malformation lung pulmonary hypoplasia/aplasia congenital diaphragmatic hernia , congenital lung anomaly A subject chromosomal abnormality ( e.g. , Trisomy 18 , Trisomy 13 Trisomy 21 ) severe congenital malformation ( e.g. , hydrocephalus encephalocele , tracheoesophageal fistula , abdominal wall defect , major renal anomaly ) A subject severe congenital infectious disease ( i.e. , herpes , toxoplasmosis rubella , syphilis , HIV , etc . ) A subject evidence severe sepsis septic shock due active infection Screening A subject underwent surgical procedure within 72 hour study drug administration anticipate surgical procedure within 72 hour follow study drug administration A subject administer surfactant within 24 hour study drug administration A subject bilateral grade 3 4 intracranial hemorrhage A subject active pulmonary hemorrhage active air leak syndrome Screening A subject currently participate interventional clinical trial A subject , opinion Principal Investigator , consider inappropriate trial due reason list</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>14 Days</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Mesenchymal Stem Cells</keyword>
	<keyword>Human Umbilical Cord Blood</keyword>
	<keyword>Premature Infants</keyword>
	<keyword>Bronchopulmonary Dysplasia</keyword>
	<keyword>Chronic Lung Disease</keyword>
	<keyword>Cell Therapy</keyword>
</DOC>